GSA Capital Partners’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-98,727
Closed -$536K – 2245
2026
Q2
$536K Buy
+98,727
New +$415K 0.03% 957
2026
Q1
– Sell
-70,654
Closed -$252K – 2157
2025
Q4
$252K Buy
+70,654
New +$262K 0.02% 1270
2025
Q2
– Sell
-28,529
Closed -$33K – 2152
2025
Q1
$33K Buy
+28,529
New +$22.1K ﹤0.01% 1567

Other funds holding STLN

GSA Capital Partners's STLN Position: Q3 2026 in Review

GSA Capital Partners sold out of Starling Oncology (STLN) in Q3 2026, closing a stake of 98,727 shares — an estimated $536K sold.

GSA Capital Partners first reported a position in STLN in Q1 2025 and held it in 3 quarters. The position peaked at $536K in Q2 2026. 130 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • GSA Capital Partners reported no remaining Starling Oncology position as of Q3 2026 after selling out during the quarter.
  • GSA Capital Partners sold 98,727 Starling Oncology shares in Q3 2026, an estimated $536K.
  • GSA Capital Partners first reported a position in Starling Oncology in Q1 2025 and held it in 3 quarters.
  • GSA Capital Partners's Starling Oncology position peaked at $536K in Q2 2026.
  • 130 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.